Express Scripts CMO: Harvoni 'price is wrong'

Express Scripts Holding Co. (NASDAQ:ESRX) CMO Steven Miller compared the price of Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) with expensive Orphan drugs in a (see BioCentury Extra, Oct. 10).

Miller's post listed the monthly costs of the 25 most expensive drugs billed through the U.S. pharmacy benefit. Harvoni, the highest-ranked non-Orphan drug, came in at 17. The post did not note that the Orphan drugs on the list must be taken chronically, while Harvoni is a 12-week course that resulted in cure rates of 87-99% in Phase III trials. ...